Med. praxi. 2022;19(5):367-369 | DOI: 10.36290/med.2022.057

The modern therapy of hypertension with combination therapy

MUDr. Barbora Nussbaumerová, Ph.D.
Centrum preventivní kardiologie, II. interní klinika LF a FN v Plzni, UK v Praze

Arterial hypertension is one of the most important modifiable cardiovascular risk factors. A combination of antihypertensive therapy should be used in most patients to compensate blood pressure values. The guidelines recommend starting the treatment with a combination of a renin-angiotensin - system inhibitor in combination with a calcium channel blocker or a diuretic. The missing drug should be added if needed. The fixed combination should be preferred because of better compliance and effectiveness.

Keywords: hypertension, fixed combination, guidelines, ACE inhibitors.

Accepted: November 22, 2022; Published: November 29, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nussbaumerová B. The modern therapy of hypertension with combination therapy. Med. praxi. 2022;19(5):367-369. doi: 10.36290/med.2022.057.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cífková R, Bruthans J, Adámková V, et al. Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006-2009. Studie Czech post­‑MONICA. Cor Vasa. 2011;53:220-229. Go to original source...
    2. Widimský J, Filipovský J, Ceral J, et al. Doporučení pro diagnostiku a léčbu arteriální hypertenze. ČSH 2017. Hypertenze Kardiovaskulární Prevence. 2018;Suppl:19.
    3. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. Go to original source... Go to PubMed...
    4. Simons LA, Chung E, Ortiz M. Long term persistence with single pill, fixed dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience. Current medical research and opinion. 2017;33(10):1783-1787. doi: 10.1080/03007995.2017.1367275. PubMed PMID: 28805468; eng. Go to original source... Go to PubMed...
    5. Verma AA, Khuu W, Tadrous M, et al. Fixed­‑dose combination antihypertensive medications, adherence, and clinical outcomes: A population­‑based retrospective cohort study. PLoS Med. 2018;15(6):e1002584. Published 2018 Jun 11. doi:10.1371/journal.pmed.1002584 Go to original source... Go to PubMed...
    6. Rea F, Corrao G, Merlino L, et a. Early cardiovascular protection by initial two­‑drug fixed­‑dose combination treatment vs. monotherapy in hypertension. Eur Heart J. 2018;39(40):3654-3661. doi:10.1093/eurheartj/ehy420. Go to original source... Go to PubMed...
    7. Visseren FLJ, Mach F, Smulders YM, et al; ESC Scientific Document Group; ESC National Cardiac Societies. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484. PMID: 34458905. Go to original source... Go to PubMed...
    8. Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin­‑converting enzyme inhibitors and angiotensin II receptor blockers on all­‑cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus. JAMA Intern Med. 2014;174:773-785. Go to original source... Go to PubMed...
    9. Ferrari R. Angiotensin­‑converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert rev Cardiovasc Ther. 2005;3:15-29. Go to original source... Go to PubMed...
    10. Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study; PERTINENT. Cardiovasc Res. 2007;73:237-246. Go to original source... Go to PubMed...
    11. Bertrand ME, Ferrari R, Remme WJ, et al. Clinical synergy of perindopril and calcium‑channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J. 2010;159(5):795-802. doi: 10.1016/j.ahj.2009. 12. 042. PubMed PMID: 20435188; eng. Go to original source... Go to PubMed...
    12. Cosentino F, Grant PJ, Aboyans V, et al; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre­‑diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. doi: 10.1093/eurheartj/ehz486. Erratum in: Eur Heart J. 2020 Dec 1;41(45):4317. PMID: 31497854. Go to original source... Go to PubMed...
    13. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipinu adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo‑Scandinavian Cardiac Outcomes Trial‑Blood Pressure Lowering Arm (ASCOT‑BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. doi: S0140-6736(05)67185- 1 (pii);10.1016/S0140-6736(05)67185-1 (doi). Go to original source... Go to PubMed...
    14. Gupta A, et al. Long term benefits of blood pressure treatment on the incidence of atrial fibrlation, heart failure and cardiovascular morbidity and mortality: 20-years follow­‑up of ASCOT­‑LEGACY. J Hypertens. 2021;39(e­‑Supplement 1). Go to original source...
    15. Hatalová K, Hatala R, et al. Clin Drug Investig. 2012;32(9):603-612. Go to original source... Go to PubMed...
    16. Glezer MG. Antihypertensive Effect of Switching to a Fixed Perindopril/Amlodipine Combination in Patients Ineffectively Treated by Free Sartan­‑Containing Combinations. Results of the AVANGARD Study. Kardiologiia. 2019;59(10):31-38. Russian. doi: 10.18087/cardio.2019. 10. n731. PMID: 31615386. Go to original source...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.